Integrated DNA Technologies (IDT) – Statement

March 11th, 2020

Integrated DNA Technologies (IDT) is proud to play an important role in the fight against 2019-nCoV. We are the first company in the nation to have our primer and probe kits approved by the US Centers for Disease Control and Prevention (CDC). Our primer and probe kits are a key component of the CDC testing protocol for the diagnosis and detection of COVID-19, for which the CDC obtained Emergency Use Authorization (EUA). As of March 9, IDT has shipped, and CDC has qualified, primer and probe kits sufficient to enable over 1 million tests to be conducted pursuant to the CDC EUA testing protocol. IDT expects to manufacture sufficient primer and probe kits to enable an additional 2.5 million tests the week of March 9, and 5 million tests per week starting March 16, and thereafter. IDT will also continue to supply primer and probe kits to research laboratories to assist them in the development of a COVID-19 vaccine.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists in researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.